Trial Profile
A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2017
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Biogen
- 20 Nov 2015 Planned End Date changed from 1 Mar 2017 to 1 Feb 2016 as reported by as reported by ClinicalTrials.gov.
- 20 Nov 2015 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2016 as reported by as reported by ClinicalTrials.gov.
- 20 Nov 2015 Status changed from recruiting to discontinued as reported by as reported by ClinicalTrials.gov record.